Ferric Carboxymaltose in Heart Failure with Iron Deficiency

In patients with heart failure with reduced ejection fraction and iron deficiency, ferric carboxymaltose therapy did not appear to differ from placebo in the composite of death, heart-failure hospitalizations, or walk distance.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 389; no. 11; pp. 975 - 986
Main Authors: Mentz, Robert J., Garg, Jyotsna, Rockhold, Frank W., Butler, Javed, De Pasquale, Carmine G., Ezekowitz, Justin A., Lewis, Gregory D., O’Meara, Eileen, Ponikowski, Piotr, Troughton, Richard W., Wong, Yee Weng, She, Lilin, Harrington, Josephine, Adamczyk, Robert, Blackman, Nicole, Hernandez, Adrian F.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 14.09.2023
Subjects:
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with heart failure with reduced ejection fraction and iron deficiency, ferric carboxymaltose therapy did not appear to differ from placebo in the composite of death, heart-failure hospitalizations, or walk distance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2304968